The synthetic biology concept continued to be strong, with Channing Biotech surging 15%. Previously, Blue Biotech went out of the 3rd straight market, with Boen Group, Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou leading the way in gains. According to the news, recently, the Shenzhen Synthetic Biology Industry Private Equity Investment Fund Partnership (Limited Partnership) was established. The executive partner is Shenzhen Venture Capital Red Earth Private Equity Investment Fund Management (Shenzhen) Co., Ltd., with an investment amount of 1.5 billion yuan. Earlier, Tan Tianwei, an Academician of the Chinese Academy of Engineering, said that currently, under the leadership of the Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Science and Technology and other national ministries and departments are jointly developing a national action plan on biotechnology and biomanufacturing, which is expected to be introduced in the near future.